Amicus Therapeutics (FOLD) Soars to 52-Week High on ‘Strong Buy' Reco [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Amicus jumped to a new 52-week high on Friday, as investors took heart from an investment firm's optimistic coverage and bullish rating for its stock. At intra-day trading, the stock climbed to its highest price of $10.85 before trimming a few cents to finish the session just up by 6.57 percent at $10.55 apiece. Pixabay/Public Domain In a market report, Zacks Research issued a “strong buy” recommendation for Amicus Therapeutics, Inc. (NASDAQ:FOLD), saying that there could be plenty of upside left in the stock, with the consensus price target of $15.90 implying a potential upside of 50.7 percent from its latest closing price. Additionally, Zacks highlighted several analysts' higher EPS targets for the stock, boosted by optimism about Amicus Therapeutics, Inc.'s (NASDAQ:FOLD) ability to report better-than-expected earnings. Amicus Therapeutics, Inc. (NASDAQ:FOLD) is a global biotechnology company focused on discovering, developing, and delivering novel, high-quality medicines
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT [Yahoo! Finance]Yahoo! Finance
- Why Amicus Therapeutics (FOLD) Is Up 6.6% After Bullish Analyst Upgrades On Earnings Outlook [Yahoo! Finance]Yahoo! Finance
- Assessing Amicus Therapeutics (FOLD) Valuation as Shares Gain 11% Over Past Month [Yahoo! Finance]Yahoo! Finance
- How Strong Galafold and Pombiliti Sales Helped Amicus Therapeutics (FOLD) Surpass Expectations and Shift Its Outlook [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
FOLD
Earnings
- 11/4/25 - Beat
FOLD
Sec Filings
- 12/3/25 - Form 4
- 12/3/25 - Form 4
- 12/3/25 - Form SCHEDULE
- FOLD's page on the SEC website